BioAdvance — 2018 Investments
1 investments dated 2018 · listed companies and verified rows first · show all
KaloCytekalocyte.cominApr 2018
KaloCyte develops ErythroMer, a dried, shelf-stable artificial red blood cell for use in emergency and trauma care when stored blood is unavailable or in short supply.
BiotechDeep TechHealthtechMedical DevicesBaltimore, US
Allan Doctor(Co-Founder & CSO)inDipanjan Pan(Co-Founder, Chief Technical Officer)inPhilip Spinella(Co-Founder, Chief Medical Officer)inDaniel Getman(Director)Gregory Lanza(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.